ASITAGAB-100 Tablet , a pharmaceutical formulation by Asitanila Remedies, presents Gabapentin (1-(aminomethyl)cyclohexaneacetic acid) at a precisely calibrated dosage of 100 mg per tablet. Gabapentin exhibits a unique pharmacological profile, primarily indicated for the management of neuropathic pain syndromes and as an adjunct in the treatment of partial seizures with or without secondary generalization. Pharmacological Action of ASITAGAB -100 tab The mechanism of action of Asitagab-100 is characterized by its high affinity binding to the alpha2delta (α2δ) subunit of voltage-gated calcium channels (VGCCs) within the central nervous system. This interaction leads to a reduction in calcium influx at presynaptic nerve terminals, thereby inhibiting the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This neuromodulatory effect contributes to the attenuation of neuronal hyperexcitability implicated in neuropathic pain and seizure propagation. Notably, Asitagab does not exhibit significant binding to GABA receptors, benzodiazepine receptors, or voltage-gated sodium channels, distinguishing its mechanism from other anticonvulsant and analgesic agents. Etymology of the Brand Name, ASITAGAB 100- A Synergistic Nomenclature The brand name \"ASITAGAB\" is likely a strategic amalgamation of the company\'s name, Asitanila, and a recognizable stem of the active pharmaceutical ingredient, Gabapentin. This linguistic fusion serves to create a distinctive yet easily identifiable brand name that links the product directly to its manufacturer and active component, facilitating recall and prescription. Advanced Manufacturing of ASITAGAB-100 tablets : Asitanila Remedies employs state-of-the-art pharmaceutical manufacturing processes for ASITAGAB-100, adhering to stringent Good Manufacturing Practices (GMP) as mandated by regulatory authorities. These advanced techniques ensure: · Uniformity of Dosage Units: Each ASITAGAB-100 tablet undergoes rigorous in-process controls and final product testing to guarantee a consistent Gabapentin content of 100 mg ± a predefined acceptance range, ensuring dose accuracy and therapeutic reliability. · Optimized Bioavailability Profile: Formulation development focuses on achieving optimal drug dissolution and subsequent absorption in the gastrointestinal tract, contributing to predictable pharmacokinetic parameters and clinical efficacy. · Stringent Quality Assurance: Comprehensive analytical testing, including high-performance liquid chromatography (HPLC) and dissolution testing, is performed to verify the purity, potency, and stability of ASITAGAB-100, ensuring patient safety and product quality throughout its shelf life.